Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Peritoneal Neoplasms 2Ovarian Neoplasms 2Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma 1

Interventions

Carboplatin 44Paclitaxel 41Cyclophosphamide 21Topotecan 19Cisplatin 18Peripheral Blood Stem Cell Transplantation 15Filgrastim 15Docetaxel 15Gemcitabine 13Bevacizumab 13liposomal doxorubicin 11Hyperthermic Intraperitoneal Chemotherapy 11sargramostim 9Therapeutics 8Immunohistochemistry 8Psychiatric Rehabilitation 7Drug Therapy 7Amifostine 7pembrolizumab 6olaparib 6Taxes 6Surveys and Questionnaires 6Melphalan 6Flow Cytometry 6Early Intervention, Educational 6Chemotherapy, Adjuvant 6niraparib 5denileukin diftitox 5Surgical Procedures, Operative 5Immunoenzyme Techniques 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Ovarian Epithelial × catumaxomab × Clear all
NCT01815528 2015-02-18

Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

Charite University, Berlin, Germany

Phase 2 Completed
2 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡